Multifunctional Magnetic Resonance (MR) for Radiotherapy Planning in Prostate Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01006564|
Recruitment Status : Unknown
Verified November 2009 by Royal Marsden NHS Foundation Trust.
Recruitment status was: Recruiting
First Posted : November 3, 2009
Last Update Posted : November 3, 2009
|Condition or disease||Intervention/treatment||Phase|
|Prostate Cancer||Other: Imaging Investigations (not radiation) Other: Other||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||30 participants|
|Intervention Model:||Single Group Assignment|
|Official Title:||Multifunctional MR for Radiotherapy Planning in Prostate Cancer|
|Study Start Date :||March 2009|
|Estimated Primary Completion Date :||June 2011|
|Estimated Study Completion Date :||June 2011|
Other: Imaging Investigations (not radiation)
- Comparison of dose distributions produced by rival radiotherapy plans judged using radiobiological model predictions of Tumour Control Probability (TCP) and Normal Tissue Complication Probability (NTCP).
- Comparison of reproducibility of registration algorithms for mapping functional MR data acquired before hormone therapy to MR anatomical data acquired after hormone therapy and prior to radiotherapy.
- Comparison of reproducibility of registration of functional and MR data with computed tomography (CT) data using gold seed registration, assessing reproducibility and positioning issues.
- Comparison of image quality, registration reproducibility and gland distortion of internal and external imaging coils for MRI image acquisition and registration of the prostate.
- Comparison of dose distributions produced by rival radiotherapy plans judged using three standard dose-volume constraints for targets and normal tissues and careful examination of the 3D dose distribution.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01006564
|Contact: Dr Nandita deSouzafirstname.lastname@example.org|
|Royal Marsden NHS Foundation Trust||Recruiting|
|Sutton, Surrey, United Kingdom, SM2 5PT|
|Principal Investigator:||Dr Nandita deSouza||CRUK Clinical Magnetic Resonance Research Group|